Anti-VEGF drugs by intravitreal injection:○Ranibizumab, mAb, targets all VEGF-A isoforms, FDA approved in 2007○Aflibercept, Fusion Protein, targets all VEGF-A isoforms, FDA approved in 2011○Bevacizumab, mAb, targets all VEGF-A isoforms, in use for AMD treatment since 2015 ○Brolucizumab, mAb, targets all VEGF-A isoforms, FDA approved in 2019. This evidence concerns the gene VEGFA and age-related macular degeneration.